May 13, 2013
Bioniche Engages Evercore Partners to Assist in the Divestment of its Animal Health Business

May 8, 2013
Bioniche Life Sciences Inc. Reports Q3, Fiscal 2013 Results

Latest TSX stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.

Latest ASX stock price

All prices delayed at least 20 minutes.
Source: ASX Inc.

Bioniche Life Sciences Inc. is a leading, fully-integrated biopharmaceutical company that discovers, develops, manufactures, and markets proprietary products for human and animal health markets worldwide. 

The information contained in the Company’s news releases was accurate at the time of posting on this website, but the information may be superseded by subsequent corporate disclosures.

Media Coverage

For recent media coverage of Bioniche Life Sciences Inc. click here >>

Latest News

May 13, 2013
Bioniche Engages Evercore Partners to Assist in the Divestment of its Animal Health Business more...

May 8, 2013
Bioniche Life Sciences Inc. Reports Q3, Fiscal 2013 Results more...

May 4, 2013
Bioniche Life Sciences Inc. Responds to Dissident Request for Shareholder Meeting more...

More News

Bioniche Key Facts

Founded: 1979

President & CEO:
Graeme McRae

TSX stock symbol:
 

Fiscal year-end:
June 30

2012 revenues:
C$32 million

Headquarters:
Belleville, Ontario

Employees worldwide:
200+

Business divisions:
Human Health,
Animal Health,
One Health

Focus areas:
Human Health:
cancer, immunomodulation

Animal Health:
reproduction, vaccines, replacement of antibiotics

One Health: E. coli O157 vaccine, other veterinary biopharmaceutical products to address diseases in livestock which may have an effect on human health

Top products:

Animal Health:
Folltropin®-V, MAP®-5